Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 12 of 2077 for:    ESTRADIOL

Comparative Bioavailability of Two Injectable Suspension Formulations of Medroxyprogesterone Acetate+Estradiol Cypionate

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03443089
Recruitment Status : Completed
First Posted : February 22, 2018
Last Update Posted : February 23, 2018
Sponsor:
Collaborator:
Biolab Sanus Farmaceutica
Information provided by (Responsible Party):
Gilberto De Nucci, Galeno Desenvolvimento de Pesquisas Clínicas

Brief Summary:
This clinical trial evaluated the comparative bioavailability of two injectable suspension formulations of medroxyprogesterone acetate + estradiol cypionate, a test (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and a reference formulation (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.) in healthy female volunteers after a single intramuscular dose administration. In addition, this study also evaluated the safety and tolerability of these drugs.

Condition or disease Intervention/treatment Phase
Contraception Drug: Test formulation Drug: Reference formulation Phase 1

Detailed Description:

This study was performed in a monocentric, open label, parallel design, with 2 treatments, 1 period, in which twelve subjects received the test product (Depomês®, 25 mg/mL medroxyprogesterone acetate + 5 mg/mL estradiol cypionate, Biolab Sanus Farmacêutica Ltda.) and twelve subjects received the reference product (Cyclofemina®, 25 mg/0.5 mL medroxyprogesterone acetate + 5 mg/0.5 mL estradiol cypionate, Millet Roux Ltda.). The formulations (test or reference) were administered in a single intramuscular dose (1 ampoule) after an overnight fast (approximately 8 h). Blood samples (9 mL) were collected via a venous catheter into heparinized tubes at times pre-dose (0 h) and 6, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, 1008, 1176, 1344, 1512, 1680, 1848, and 2016 h after drug administration to measure medroxyprogesterone; and pre-dose (-48, -24 and 0 h) e 2, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, 240, 288, 336, 432, 504, 672, 840, and 1008 h after drug administration to measure estradiol cypionate.

The safety assessment was based on recording adverse events throughout the study duration. The subjects systolic and diastolic pressures, heart rate and temperature were determined prior and at approximately 4, 8 and 12 h after drug administration. The clinical evaluation and the laboratory tests were also performed at the end of the study.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Comparative Bioavailability Study of Two Injectable Suspension Formulations, a Test (Medroxyprogesterone Acetate 25 mg/mL + Estradiol Cypionate 5 mg/mL) vs. a Reference (Medroxyprogesterone Acetate 25 mg/AMP + Estradiol Cypionate 5 mg/AMP)
Actual Study Start Date : March 31, 2017
Actual Primary Completion Date : April 2, 2017
Actual Study Completion Date : August 1, 2017


Arm Intervention/treatment
Experimental: Test formulation
Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/mL+ estradiol cypionate 5 mg/mL (Depomês®, Biolab Sanus Farmacêutica Ltda.)
Drug: Test formulation
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after an overnight fast.

Active Comparator: Reference formulation
Single intramuscular dose administration (1 ampoule) of medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole (Cyclofemina®, Millet Roux Ltda.)
Drug: Reference formulation
Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/ampole + estradiol cypionate 5 mg/ampole after an overnight fast.




Primary Outcome Measures :
  1. Measurement of medroxyprogesterone acetate and estradiol cypionate plasma levels [ Time Frame: 0-1008 hours after drug administration ]
    Blood sampling for the determination of plasma levels of medroxyprogesterone acetate and estradiol cypionate in participants of each treatment group.

  2. Measurement of estradiol cypionate plasma levels [ Time Frame: -48 to 1008 hours after drug administration ]
    Blood sampling for the determination of plasma levels of estradiol cypionate in participants of each treatment group.


Secondary Outcome Measures :
  1. Maximum Plasma Concentration (Cmax) of medroxyprogesterone acetate [ Time Frame: 0 - 1008 hours after drug administration ]
    Determination of maximum plasma concentration of medroxyprogesterone acetate on plasma concentrations of samples obtained.

  2. Maximum Plasma Concentration (Cmax) of estradiol cypionate [ Time Frame: 0 - 1008 hours after drug administration ]
    Determination of maximum plasma concentration of estradiol cypionate on plasma concentrations of samples obtained.

  3. Area Under the Curve (AUC) of medroxyprogesterone acetate [ Time Frame: 0 - 1008 hours after drug administration ]
    Determination of area Under the Curve of medroxyprogesterone acetate from plasma concentrations versus time curve of samples obtained.

  4. Area Under the Curve (AUC) of estradiol cypionate [ Time Frame: 0 - 1008 hours after drug administration ]
    Determination of area Under the Curve of estradiol cypionate from plasma concentrations versus time curves of samples obtained.

  5. Number of adverse events per participant [ Time Frame: Up to 1008 hours after drug administration ]
    Number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body-mass index (BMI) ≥19.0 kg/m² and ≤ 27.5 kg/m²
  • With regular cycles, without use of hormonal contraceptives (pills at least 3 months and injectables at least 1 year) and not using hormone replacement therapy
  • Not pregnant or breastfeeding
  • Good state of health
  • Non-smoker or ex-smoker for at least 6 month
  • Written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion Criteria:

  • Existing cardiac, hepatic and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability and/or pharmacokinetics and/or pharmacodynamics of the active ingredient
  • History of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
  • Known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
  • Subjects with severe allergies or multiple drug allergies, unless it is judged as not relevant for the clinical trial by the investigator
  • Positive anti-HIV-test (if positive to be verified by western blot), HBs-AGtest (if positive to be verified by test for HBc-IgM) or anti-HCV-test
  • Admitted for any reason up to 8 weeks before the start of the first treatment period of this study
  • History of or current drug or alcohol dependence
  • Subjects who are on a diet which could affect the pharmacokinetics of the active ingredient
  • Regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
  • Blood donation or other blood loss of more than 400 ml within the last 3 months prior to individual enrolment of the subject
  • Participation in a clinical trial during the last 6 months prior to individual enrolment of the subject
  • Positive pregnancy test, delivery or abortion in the 12 weeks prior to the planned hospitalization date.
  • Subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03443089


Locations
Layout table for location information
Brazil
Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
Campinas, SP, Brazil
Sponsors and Collaborators
Galeno Desenvolvimento de Pesquisas Clínicas
Biolab Sanus Farmaceutica
Investigators
Layout table for investigator information
Principal Investigator: Gilberto De Nucci, Doctor Galeno Desenvolvimento de Pesquisas Clinicas Ltda

Layout table for additonal information
Responsible Party: Gilberto De Nucci, Doctor, Galeno Desenvolvimento de Pesquisas Clínicas
ClinicalTrials.gov Identifier: NCT03443089     History of Changes
Other Study ID Numbers: GDN 022/16
First Posted: February 22, 2018    Key Record Dates
Last Update Posted: February 23, 2018
Last Verified: February 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Gilberto De Nucci, Galeno Desenvolvimento de Pesquisas Clínicas:
medroxyprogesterone acetate
estradiol cypionate
bioavailability
monthly contraceptive
Additional relevant MeSH terms:
Layout table for MeSH terms
Estradiol 3-benzoate
Estradiol 17 beta-cypionate
Estradiol
Polyestradiol phosphate
Medroxyprogesterone Acetate
Medroxyprogesterone
Estrogens
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Contraceptive Agents
Reproductive Control Agents
Contraceptive Agents, Female
Contraceptives, Oral, Synthetic
Contraceptives, Oral
Contraceptive Agents, Male
Antineoplastic Agents, Hormonal
Antineoplastic Agents